JP2023546584A - Ｅｒ陽性がんに選択的な抗がん化合物 - Google Patents
Ｅｒ陽性がんに選択的な抗がん化合物 Download PDFInfo
- Publication number
- JP2023546584A JP2023546584A JP2023524127A JP2023524127A JP2023546584A JP 2023546584 A JP2023546584 A JP 2023546584A JP 2023524127 A JP2023524127 A JP 2023524127A JP 2023524127 A JP2023524127 A JP 2023524127A JP 2023546584 A JP2023546584 A JP 2023546584A
- Authority
- JP
- Japan
- Prior art keywords
- erso
- compound
- cancer
- erα
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063104933P | 2020-10-23 | 2020-10-23 | |
| US63/104,933 | 2020-10-23 | ||
| PCT/US2021/056003 WO2022087234A1 (en) | 2020-10-23 | 2021-10-21 | Anticancer compounds selective for er-positive cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546584A true JP2023546584A (ja) | 2023-11-06 |
| JP2023546584A5 JP2023546584A5 (enExample) | 2024-10-25 |
Family
ID=81290080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524127A Pending JP2023546584A (ja) | 2020-10-23 | 2021-10-21 | Ｅｒ陽性がんに選択的な抗がん化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12655104B2 (enExample) |
| EP (1) | EP4232038A4 (enExample) |
| JP (1) | JP2023546584A (enExample) |
| CN (1) | CN116723841A (enExample) |
| AU (2) | AU2021366688B2 (enExample) |
| CA (1) | CA3196210A1 (enExample) |
| IL (1) | IL302154A (enExample) |
| MX (1) | MX2023004480A (enExample) |
| WO (1) | WO2022087234A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120981469A (zh) * | 2023-02-23 | 2025-11-18 | 晨晖生物科技(香港)有限公司 | 含硼化合物及其治疗用途 |
| WO2026039467A1 (en) * | 2024-08-12 | 2026-02-19 | The Board Of Trustees Of The University Of Illinois | Hydroxyphenyl-indoline-2-one cancer therapeutics |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004502654A (ja) * | 2000-06-19 | 2004-01-29 | サノフィ−サンテラボ | 新規な１，３−ジヒドロ−２ｈ−インドール−２−オン誘導体、それらの製造方法およびそれらを含む医薬組成物 |
| JP2010525024A (ja) * | 2007-04-24 | 2010-07-22 | トポターゲット・アクティーゼルスカブ | 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2855406A (en) | 1955-05-07 | 1958-10-07 | Dann Otto | Preparation of benzopyrans and benzofurans |
| US3773759A (en) | 1972-08-21 | 1973-11-20 | Searle & Co | 1-arylideneamino-4-(2-oxo-3-phenyl-3-benzofuryl)piperazines |
| EA027139B1 (ru) | 2013-04-26 | 2017-06-30 | Бейджин, Лтд. | Замещенные 5-(3,5-диметилизоксазол-4-ил)индолин-2-оны |
| CN108440378B (zh) | 2018-03-27 | 2021-03-12 | 宁波大学 | 一种室温下碘-双氧水促进的3-氨基-2-吲哚酮衍生物的制备方法 |
| EP3817741A4 (en) * | 2018-07-03 | 2022-07-06 | The Board of Trustees of the University of Illinois | ACTIVATORS OF THE UNFOLDING PROTEIN RESPONSE |
-
2021
- 2021-10-21 WO PCT/US2021/056003 patent/WO2022087234A1/en not_active Ceased
- 2021-10-21 CA CA3196210A patent/CA3196210A1/en active Pending
- 2021-10-21 US US18/033,173 patent/US12655104B2/en active Active
- 2021-10-21 CN CN202180086814.XA patent/CN116723841A/zh active Pending
- 2021-10-21 EP EP21883881.1A patent/EP4232038A4/en active Pending
- 2021-10-21 IL IL302154A patent/IL302154A/en unknown
- 2021-10-21 MX MX2023004480A patent/MX2023004480A/es unknown
- 2021-10-21 JP JP2023524127A patent/JP2023546584A/ja active Pending
- 2021-10-21 AU AU2021366688A patent/AU2021366688B2/en active Active
-
2026
- 2026-06-02 AU AU2026204244A patent/AU2026204244A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004502654A (ja) * | 2000-06-19 | 2004-01-29 | サノフィ−サンテラボ | 新規な１，３−ジヒドロ−２ｈ−インドール−２−オン誘導体、それらの製造方法およびそれらを含む医薬組成物 |
| JP2010525024A (ja) * | 2007-04-24 | 2010-07-22 | トポターゲット・アクティーゼルスカブ | 置換３−（４−ヒドロキシフェニル）−インドリン−２−オン化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021366688A9 (en) | 2024-06-20 |
| MX2023004480A (es) | 2023-05-04 |
| US12655104B2 (en) | 2026-06-16 |
| EP4232038A4 (en) | 2024-04-10 |
| IL302154A (en) | 2023-06-01 |
| AU2021366688A1 (en) | 2023-05-25 |
| EP4232038A1 (en) | 2023-08-30 |
| AU2026204244A1 (en) | 2026-06-18 |
| CA3196210A1 (en) | 2022-04-28 |
| WO2022087234A1 (en) | 2022-04-28 |
| US20230391721A1 (en) | 2023-12-07 |
| CN116723841A (zh) | 2023-09-08 |
| AU2021366688B2 (en) | 2026-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11672785B2 (en) | Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs | |
| JP5694172B2 (ja) | カルバゾール化合物および当該化合物の治療用途 | |
| JP2022546471A (ja) | エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法 | |
| WO2020228685A1 (zh) | 含氟化合物及抗癌医药用途 | |
| TWI837402B (zh) | 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途 | |
| JP2022513959A5 (enExample) | ||
| WO2022206737A1 (zh) | 四氢萘类化合物、其制备方法及其在医药上的应用 | |
| JP2015003909A (ja) | ベンゾピラン化合物の組合せ、その組成物および使用 | |
| JP2021185193A (ja) | インデニル化合物、医薬組成物、およびその医学的使用 | |
| US20260103470A1 (en) | Androgen receptor regulation by small molecule enantiomers | |
| CA3103958A1 (en) | Activators of the unfolded protein response | |
| AU2021366688B2 (en) | Anticancer compounds selective for er-positive cancers | |
| CA2771234A1 (en) | Substituted hydrazide compounds and use thereof | |
| US12312354B2 (en) | Selective BTK irreversible inhibitors | |
| KR20210134306A (ko) | 아크릴-함유 핵 수출 조절제들 및 이들의 용도들 | |
| WO2021222738A1 (en) | Compounds for estrogen receptor positive cancers | |
| US12552806B2 (en) | Androgen receptor regulation by small molecule enantiomers | |
| US20250376477A1 (en) | Analgesic delta opioid receptor bitopic ligands | |
| WO2026039467A1 (en) | Hydroxyphenyl-indoline-2-one cancer therapeutics | |
| US11731947B2 (en) | Deuterated antimicrobial compounds | |
| EP2636667B1 (en) | Benzamide derivative with anticancer activity and preparation method and use thereof | |
| CN107266468A (zh) | 含吡唑啉结构的噻喃并嘧啶类化合物的制备及应用 | |
| EA050862B1 (ru) | Соединение тетрагидронафталина, и способ его получения, и его применение в медицине | |
| HK40061701A (en) | Fluorine-containing compound and anti-cancer medical use thereof | |
| KR20100047495A (ko) | 신규 갈바닉산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241017 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241017 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250829 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251201 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260317 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260714 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260714 |